A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous (i.v.) Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Male osteoporosis; Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 21 Mar 2018 This trial has been discontinued in Germany.
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2017 Planned End Date changed from 16 Apr 2018 to 2 Mar 2018.